1. Home
  2. TRDA vs MKLY Comparison

TRDA vs MKLY Comparison

Compare TRDA & MKLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRDA

Entrada Therapeutics Inc.

N/A

Current Price

$4.65

Market Cap

275.3M

Sector

Health Care

ML Signal

N/A

MKLY

McKinley Acquisition Corporation Class A Ordinary Shares

N/A

Current Price

$10.32

Market Cap

248.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
TRDA
MKLY
Founded
2016
2025
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
275.3M
248.1M
IPO Year
2021
2025

Fundamental Metrics

Financial Performance
Metric
TRDA
MKLY
Price
$4.65
$10.32
Analyst Decision
Strong Buy
Analyst Count
8
0
Target Price
★ $17.75
N/A
AVG Volume (30 Days)
★ 449.9K
24.4K
Earning Date
11-05-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $25,421,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$361.69
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$4.11
$9.95
52 Week High
$16.45
$10.33

Technical Indicators

Market Signals
Indicator
TRDA
MKLY
Relative Strength Index (RSI) 44.20 66.06
Support Level $4.18 $10.25
Resistance Level $5.13 N/A
Average True Range (ATR) 0.51 0.01
MACD 0.05 0.00
Stochastic Oscillator 23.15 74.26

Price Performance

Historical Comparison
TRDA
MKLY

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About MKLY McKinley Acquisition Corporation Class A Ordinary Shares

McKinley Acquisition Corp is a blank check company.

Share on Social Networks: